Der Hautarzt

, Volume 63, Issue 1, pp 10–15 | Cite as

HIV-Infektion

Leitthema
  • 597 Downloads

Zusammenfassung

Die Haut kann als Indikator für den Immunstatus fungieren. Dermatologische Markererkrankungen, bei denen ein HIV-Test erwogen werden sollte, sind u. a. ein ausgedehntes, neu aufgetretenes klinisch ausgeprägtes seborrhoisches Ekzem, eine neu diagnostizierte Psoriasis bei leerer Familienanamnese, ein ausgeprägter Herpes zoster insbesondere bei jungen Patienten, eine Haarleukoplakie der Zunge und Mollusca contagiosa bei Erwachsenen. Das Bild der HIV-Infektion hat sich in den letzten 15 Jahren stark gewandelt. Nahezu jährlich wurden neue Medikamente mit besserer Wirksamkeit, einfacheren Einnahmemodalitäten und geringeren Nebenwirkungen zugelassen, sodass bei uns die Lebenserwartung der Betroffenen in den westlichen Industrieländern annähernd normale Werte erreicht hat. Trotz besserer Behandelbarkeit bleibt die Prävention das wichtigste Mittel zur Bekämpfung der weltweiten Epidemie. Aufklärungskampagnen müssen zusätzlich die Synergien zwischen HIV und anderen sexuell übertragenen Erkrankungen berücksichtigen. Hier ist die Dermatovenerologie in besonderem Maße gefordert.

Schlüsselwörter

HIV-Infektion Dermatologische Markererkrankungen Prävention Aufklärungskampagnen Dermatovenerologie 

HIV infection

Abstract

The skin can be an indicator of decreased immunocompetence. Dermatological markers include new and extensive seborrheic eczema, psoriasis without a family history, widespread herpes zoster in young adults, oral hairy leucoplakia and mollusca in adults. In these cases an HIV test should be offered. During the last 15 years the clinical picture of HIV has changed dramatically. Almost every year new drugs with better efficacy, lower pill burden and less side effects have been approved. Life expectancy is close to normal in western countries. In spite of better treatment options, prevention is the key to stop the worldwide epidemic. Awareness campaigns have to account for the synergies between HIV and other sexually transmitted diseases. This poses a great challenge for dermatovenereology.

Keywords

HIV infections Dermatologic markers Prevention Awareness campaigns Dermatovenereology 

Notes

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Es wurden Forschungsprojekte, Beraterverträge bzw. Reisekostenerstattungen mit allen im HIV-Bereich tätigen Firmen durchgeführt.

Literatur

  1. 1.
    Anglemyer A, Rutherford GW, Baggaley RC et al (2011) Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 8:CD009153PubMedGoogle Scholar
  2. 2.
    Arastéh K (2010) 24 Wk efficacy and safety of transitioning virologically stable HIV-1 patients from IR nevirapine 200 mg BID to nevirapine XR 400 mg Q. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, USA, September 12–15 (Poster:207)Google Scholar
  3. 3.
    Clinical Trial gov. Strategic Timing of Antiretroviral Treatment (START). http://clinicaltrials.gov/ct2/show/NCT00867048Google Scholar
  4. 4.
    Cohen CJ, Andrade-Villanueva J, Clotet B et al (2011) Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 378:229–237PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen MS, Chen YQ, Mc Cauly M et al (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365:493–505PubMedCrossRefGoogle Scholar
  6. 6.
    Cooper RD, Wiebe N, Smith N et al (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51(5):496–505PubMedCrossRefGoogle Scholar
  7. 7.
    DAD Study Group, Sabin CA, Worm SW et al (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD study: a multi-cohort collaboration. Lancet 371:1417–1426CrossRefGoogle Scholar
  8. 8.
    Delaney KP, Branson BM, Uniyal A et al (2011) Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis 52:257–263PubMedCrossRefGoogle Scholar
  9. 9.
    Deeks ED, Perry CM (2010) Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. Drugs 70:2315–2338PubMedCrossRefGoogle Scholar
  10. 10.
    Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion (Stand März 2010). http://www.daignet.deGoogle Scholar
  11. 11.
    Ding X, Andraca-Carrera E, Cooper C et al (2011) No association of myocardial infarction with ABC use: an FDA Meta-analysis18th CROI 2011, Boston, Poster 808Google Scholar
  12. 12.
    EACS Guidelines: Clinical management and treatment of HIV-infected adults in Europe. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-pdf/1_treatment_of_hiv_infected_adults.pdfGoogle Scholar
  13. 13.
    Efficacy and safety of GSK biologicals HIV vaccine in antiretroviral therapy (ART)-naive HIV-1 infected persons. http://clinicaltrials.gov/ct2/show/NCT01218113Google Scholar
  14. 14.
    Elion R (2010) The single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; Quad) maintains a high rate of virologic suppression, and cobicistat (COBI) is an effective pharmacoenhancer through 48 weeks ICAAC 2010; Abstract H-938bGoogle Scholar
  15. 15.
    Gathe J (2010) Comparison of 48 week efficacy and safety of 400 mg QD nevirapine extended release formulation (Viramune XR) versus 200 mg BID nevirapine immediate release formulation (Viramune IR) in combination with Truvada in antiretroviral (ARV) naive HIV-1 infected patients (VERxVE). XVIII International AIDS Conference, Vienna, Austria; July 18–23, 2010 oral presentationGoogle Scholar
  16. 16.
    Lewden C, May T, Rosenthal E (2008) Changes in causes of death among adults infected by hiv between 2000 and 2005: the „Mortalité 2000 and 2005“ Surveys (ANRS EN 19 and Mortavic). J Acquir Immune Defic Syndr 48:590–598PubMedCrossRefGoogle Scholar
  17. 17.
    Mallal S, Phillips E, Carosi G et al (2008) PREDICT-1 study team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568–579PubMedCrossRefGoogle Scholar
  18. 18.
    Mills AM, Nelson M, Jayaweera D et al (2009) Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. Aids 23:1679–1688PubMedCrossRefGoogle Scholar
  19. 19.
    Molina JM, Andrade-Villanueva J, Echevarria J et al (2008) Once daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 372:646–655PubMedCrossRefGoogle Scholar
  20. 20.
    Molina JM, Cahn P, Grinsztejn B et al (2011) Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 378:238–246PubMedCrossRefGoogle Scholar
  21. 21.
    Mullins TL, Kollar LM, Lehmann C, Kahn JA (2010) Changes in human immunodeficiency virus testing rates among urban adolescents after introduction of routine and rapid testing. Arch Pediatr Adolesc Med 164(9):870–874PubMedCrossRefGoogle Scholar
  22. 22.
    Pozniak AL, Gallant JE, DeJesus E et al (2006) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes – a 96-week analysis. J Acquir Immune Defic Syndr 43(5):535–540PubMedGoogle Scholar
  23. 23.
    Pulido F, Estrada V, Baril JG et al (2009) Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. HIV Clin Trials 10:76–87PubMedCrossRefGoogle Scholar
  24. 24.
    Qualitätssicherungsvereinbarung HIV/AIDS. http://www.kbv.de/23945.htmlGoogle Scholar
  25. 25.
    RKI (2011) HIV Infektionen und AIDS-Erkrankungen in Deutschland. Epidemiol Bull 21:179–198Google Scholar
  26. 26.
    Robinson P, Wit FW, Lange JM (2004) 2NN study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 363:1253–1263PubMedCrossRefGoogle Scholar
  27. 27.
    Rockstroh JK, Lennox JL, Dejesus E et al (2011) Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 53:807–816PubMedCrossRefGoogle Scholar
  28. 28.
    Smith KY, Patel P, Fine D et al (2009) Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 23:1547–1556PubMedCrossRefGoogle Scholar
  29. 29.
    Sax P, Tierney C, Collier A (2008). ACTG 5202: shorter time to virologic failure with ABC/3TC than TDF/FTC in treatment-naive subjects with HIV RNA > 100,000. XVII International AIDS Conference. August 3–8 Mexico City (Abstract THAB0303)Google Scholar
  30. 30.
    Welz T, Childs K, Ibrahim F et al (2010) Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 24:1923–1928PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Interdisziplinäre Immunologische Ambulanz St. Josef Hospital BochumBochumDeutschland

Personalised recommendations